Complement C3 deficiency attenuates chronic hypoxia-induced pulmonary hypertension in mice

PLoS ONE

Volumn 6, Issue 12, 2011, Pages

  Bauer, Eileen M ^a   Zheng, Han ^a   Comhair, Suzy ^b   Erzurum, Serpil ^b   Billiar, Timothy R ^a   Bauer, Philip M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C3A; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C5A; ENDOTHELIN 1; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; PADGEM PROTEIN; THROMBOPLASTIN; BIOLOGICAL MARKER; FIBRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERIOLE; ARTICLE; ATTENUATION; BLEEDING TIME; BLOOD VESSEL WALL; C57BL 6 MOUSE; COMPLEMENT ACTIVATION; COMPLEMENT C3 DEFICIENCY; COMPLEMENT DEFICIENCY; COMPLEMENT DEPOSITION; CONTROLLED STUDY; FIBRIN DEPOSITION; FLOW CYTOMETRY; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; IMMUNOHISTOCHEMISTRY; MALE; MOUSE; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; SYSTOLIC BLOOD PRESSURE; THROMBOCYTE ACTIVATION; VASCULAR RESISTANCE; WILD TYPE; ANIMAL; ANOXIA; C57BL MOUSE; CELL PROLIFERATION; CHRONIC DISEASE; GENE DELETION; GENETICS; METABOLISM; PATHOLOGY; PULMONARY ARTERY; SMOOTH MUSCLE FIBER; UPREGULATION; VASCULAR ENDOTHELIUM;

ANIMALS; ANOXIA; ARTERIOLES; BIOLOGICAL MARKERS; CELL PROLIFERATION; CHRONIC DISEASE; COMPLEMENT C3; COMPLEMENT C3A; COMPLEMENT C5A; ENDOTHELIUM, VASCULAR; FIBRIN; GENE DELETION; HUMANS; HYPERTENSION, PULMONARY; MICE; MICE, INBRED C57BL; MYOCYTES, SMOOTH MUSCLE; PLATELET ACTIVATION; PULMONARY ARTERY; THROMBOPLASTIN; UP-REGULATION;

EID: 83355176600     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0028578     Document Type: Article

References (50)

1. D'Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, et al. (1991) Survival in patients with primary pulmonary hypertension. Results from a national prospective registry. Ann Intern Med 115: 343-349.
2. Humbert M, Morrell NW, Archer SL, Stenmark KR, MacLean MR, et al. (2004) Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 43: 13S-24S.
3. Mathew R, (2010) Inflammation and pulmonary hypertension. Cardiol Rev 18: 67-72.
4. Markiewski MM, Lambris JD, (2007) The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 171: 715-727.
5. Pangburn MK, Rawal N, (2002) Structure and function of complement C5 convertase enzymes. Biochem Soc Trans 30: 1006-1010.
6. Bjork J, Hugli TE, Smedegard G, (1985) Microvascular effects of anaphylatoxins C3a and C5a. J Immunol 134: 1115-1119.
7. Morel DR, Zapol WM, Thomas SJ, Kitain EM, Robinson DR, et al. (1987) C5a and thromboxane generation associated with pulmonary vaso- and broncho-constriction during protamine reversal of heparin. Anesthesiology 66: 597-604.
8. Morganroth ML, Schoeneich SO, Till GO, Ward PA, Horvath SJ, et al. (1990) C3a57-77, a C-terminal peptide, causes thromboxane-dependent pulmonary vascular constriction in isolated perfused rat lungs. Am Rev Respir Dis 141: 296-300.
9. Abdul-Salam VB, Paul GA, Ali JO, Gibbs SR, Rahman D, et al. (2006) Identification of plasma protein biomarkers associated with idiopathic pulmonary arterial hypertension. Proteomics 6: 2286-2294.
10. Zhang J, Zhang Y, Li N, Liu Z, Xiong C, et al. (2009) Potential diagnostic biomarkers in serum of idiopathic pulmonary arterial hypertension. Respir Med 103: 1801-1806.
11. Aldred MA, Comhair SA, Varella-Garcia M, Asosingh K, Xu W, et al. (2010) Somatic chromosome abnormalities in the lungs of patients with pulmonary arterial hypertension. Am J Respir Crit Care Med 182: 1153-1160.
12. Fijalkowska I, Xu W, Comhair SA, Janocha AJ, Mavrakis LA, et al. (2010) Hypoxia inducible-factor1alpha regulates the metabolic shift of pulmonary hypertensive endothelial cells. Am J Pathol 176: 1130-1138.
13. Masri FA, Xu W, Comhair SA, Asosingh K, Koo M, et al. (2007) Hyperproliferative apoptosis-resistant endothelial cells in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L548-554.
14. Xu W, Kaneko FT, Zheng S, Comhair SA, Janocha AJ, et al. (2004) Increased arginase II and decreased NO synthesis in endothelial cells of patients with pulmonary arterial hypertension. FASEB J 18: 1746-1748.
15. Zuckerbraun BS, Shiva S, Ifedigbo E, Mathier MA, Mollen KP, et al. (2010) Nitrite potently inhibits hypoxic and inflammatory pulmonary arterial hypertension and smooth muscle proliferation via xanthine oxidoreductase-dependent nitric oxide generation. Circulation 121: 98-109.
16. Aytekin M, Comhair SA, de la Motte C, Bandyopadhyay SK, Farver CF, et al. (2008) High levels of hyaluronan in idiopathic pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 295: L789-799.
17. Phillippi JA, Klyachko EA, Kenny JPt, Eskay MA, Gorman RC, et al. (2009) Basal and oxidative stress-induced expression of metallothionein is decreased in ascending aortic aneurysms of bicuspid aortic valve patients. Circulation 119: 2498-2506.
18. Bauer PM, Buga GM, Ignarro LJ, (2001) Role of p42/p44 mitogen-activated-protein kinase and p21waf1/cip1 in the regulation of vascular smooth muscle cell proliferation by nitric oxide. Proc Natl Acad Sci U S A 98: 12802-12807.
19. Huber-Lang M, Sarma JV, Zetoune FS, Rittirsch D, Neff TA, et al. (2006) Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med 12: 682-687.
20. Verdeguer F, Castro C, Kubicek M, Pla D, Vila-Caballer M, et al. (2007) Complement regulation in murine and human hypercholesterolemia and role in the control of macrophage and smooth muscle cell proliferation. Cardiovasc Res 76: 340-350.
21. Gushiken FC, Han H, Li J, Rumbaut RE, Afshar-Kharghan V, (2009) Abnormal platelet function in C3-deficient mice. J Thromb Haemost 7: 865-870.
22. Lawson CA, Yan SD, Yan SF, Liao H, Zhou YS, et al. (1997) Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation. J Clin Invest 99: 1729-1738.
23. Yan SF, Zou YS, Gao Y, Zhai C, Mackman N, et al. (1998) Tissue factor transcription driven by Egr-1 is a critical mechanism of murine pulmonary fibrin deposition in hypoxia. Proc Natl Acad Sci U S A 95: 8298-8303.
24. Sakuma M, Morooka T, Wang Y, Shi C, Croce K, et al. (2010) The intrinsic complement regulator decay-accelerating factor modulates the biological response to vascular injury. Arterioscler Thromb Vasc Biol 30: 1196-1202.
25. Cheung AK, Parker CJ, Wilcox L, (1989) Effects of two types of cobra venom factor on porcine complement activation and pulmonary artery pressure. Clin Exp Immunol 78: 299-306.
26. Firth AL, Yau J, White A, Chiles PG, Marsh JJ, et al. (2009) Chronic exposure to fibrin and fibrinogen differentially regulates intracellular Ca2+ in human pulmonary arterial smooth muscle and endothelial cells. Am J Physiol Lung Cell Mol Physiol 296: L979-986.
27. Rothlein R, Springer TA, (1986) The requirement for lymphocyte function-associated antigen 1 in homotypic leukocyte adhesion stimulated by phorbol ester. J Exp Med 163: 1132-1149.
28. Yang L, Froio RM, Sciuto TE, Dvorak AM, Alon R, et al. (2005) ICAM-1 regulates neutrophil adhesion and transcellular migration of TNF-alpha-activated vascular endothelium under flow. Blood 106: 584-592.
29. Steiner MK, Syrkina OL, Kolliputi N, Mark EJ, Hales CA, et al. (2009) Interleukin-6 overexpression induces pulmonary hypertension. Circ Res 104: 236-244 228p following 244.
30. Savale L, Tu L, Rideau D, Izziki M, Maitre B, et al. (2009) Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice. Respir Res 10: 6.
31. Soon E, Holmes AM, Treacy CM, Doughty NJ, Southgate L, et al. (2010) Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 122: 920-927.
32. Pendergrass SA, Hayes E, Farina G, Lemaire R, Farber HW, et al. (2010) Limited systemic sclerosis patients with pulmonary arterial hypertension show biomarkers of inflammation and vascular injury. PLoS One 5: e12106.
33. Nishimaki T, Aotsuka S, Kondo H, Yamamoto K, Takasaki Y, et al. (1999) Immunological analysis of pulmonary hypertension in connective tissue diseases. J Rheumatol 26: 2357-2362.
34. Rubin LJ, Badesch DB, Barst RJ, Galie N, Black CM, et al. (2002) Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 346: 896-903.
35. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD, (2007) Complement and coagulation: strangers or partners in crime? Trends Immunol 28: 184-192.
36. Maeda NY, Carvalho JH, Otake AH, Mesquita SM, Bydlowski SP, et al. (2010) Platelet protease-activated receptor 1 and membrane expression of P-selectin in pulmonary arterial hypertension. Thromb Res 125: 38-43.
37. Cathcart MC, Tamosiuniene R, Chen G, Neilan TG, Bradford A, et al. (2008) Cyclooxygenase-2-linked attenuation of hypoxia-induced pulmonary hypertension and intravascular thrombosis. J Pharmacol Exp Ther 326: 51-58.
38. White TA, Witt TA, Pan S, Mueske CS, Kleppe LS, et al. (2009) Tissue Factor Pathway Inhibitor Overexpression Inhibits Hypoxia-induced Pulmonary Hypertension. Am J Respir Cell Mol Biol.
39. Ganey PE, Sprugel KH, White SM, Wagner JG, Roth RA, (1988) Pulmonary hypertension due to monocrotaline pyrrole is reduced by moderate thrombocytopenia. Am J Physiol 255: H1165-1172.
40. Rostagno C, Prisco D, Abbate R, Poggesi L, (1991) Pulmonary hypertension associated with long-standing thrombocytosis. Chest 99: 1303-1305.
41. Christman BW, McPherson CD, Newman JH, King GA, Bernard GR, et al. (1992) An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 327: 70-75.
42. Cirillo P, Cali G, Golino P, Calabro P, Forte L, et al. (2004) Tissue factor binding of activated factor VII triggers smooth muscle cell proliferation via extracellular signal-regulated kinase activation. Circulation 109: 2911-2916.
43. Sato Y, Asada Y, Marutsuka K, Hatakeyama K, Sumiyoshi A, (1996) Tissue factor induces migration of cultured aortic smooth muscle cells. Thromb Haemost 75: 389-392.
44. Altman R, Scazziota A, Rouvier J, Gurfinkel E, Favaloro R, et al. (1996) Coagulation and fibrinolytic parameters in patients with pulmonary hypertension. Clin Cardiol 19: 549-554.
45. Bakouboula B, Morel O, Faure A, Zobairi F, Jesel L, et al. (2008) Procoagulant membrane microparticles correlate with the severity of pulmonary arterial hypertension. Am J Respir Crit Care Med 177: 536-543.
46. White RJ, Galaria II, Harvey J, Blaxall BC, Cool CD, et al. (2005) Tissue factor is induced in a rodent model of severe pulmonary hypertension characterized by neointimal lesions typical of human disease. Chest 128: 612S-613S.
47. White RJ, Meoli DF, Swarthout RF, Kallop DY, Galaria II, et al. (2007) Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 293: L583-590.
48. Yan SF, Mackman N, Kisiel W, Stern DM, Pinsky DJ, (1999) Hypoxia/Hypoxemia-Induced activation of the procoagulant pathways and the pathogenesis of ischemia-associated thrombosis. Arterioscler Thromb Vasc Biol 19: 2029-2035.
49. Yan SF, Pinsky DJ, Stern DM, (2000) A pathway leading to hypoxia-induced vascular fibrin deposition. Semin Thromb Hemost 26: 479-483.
50. Amara U, Flierl MA, Rittirsch D, Klos A, Chen H, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol 185: 5628-5636.